- Home
- CHNR vs KALA Comparison
CHNR vs KALA Comparison
Compare CHNR & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHNR
- KALA
- Stock Information
- Founded
- CHNR N/A
- KALA 2009
- Country
- CHNR China
- KALA United States
- Employees
- CHNR N/A
- KALA 38
- Industry
- CHNR Precious Metals
- KALA Biotechnology: Pharmaceutical Preparations
- Sector
- CHNR Basic Materials
- KALA Health Care
- Exchange
- CHNR Nasdaq
- KALA Nasdaq
- Market Cap
- CHNR 5.3M
- KALA 5.5M
- IPO Year
- CHNR 1995
- KALA 2017
- Fundamental
- Price
- CHNR $4.79
- KALA $0.80
- Analyst Decision
- CHNR
- KALA Buy
- Analyst Count
- CHNR 0
- KALA 3
- Target Price
- CHNR N/A
- KALA $31.50
- AVG Volume (30 Days)
- CHNR 994.4K
- KALA 686.0K
- Earning Date
- CHNR 12-12-2025
- KALA 11-07-2025
- Dividend Yield
- CHNR N/A
- KALA N/A
- EPS Growth
- CHNR N/A
- KALA N/A
- EPS
- CHNR N/A
- KALA N/A
- Revenue
- CHNR N/A
- KALA N/A
- Revenue This Year
- CHNR N/A
- KALA N/A
- Revenue Next Year
- CHNR N/A
- KALA N/A
- P/E Ratio
- CHNR N/A
- KALA N/A
- Revenue Growth
- CHNR N/A
- KALA N/A
- 52 Week Low
- CHNR $3.16
- KALA $0.74
- 52 Week High
- CHNR $8.20
- KALA $20.60
- Technical
- Relative Strength Index (RSI)
- CHNR 39.93
- KALA 26.93
- Support Level
- CHNR $5.00
- KALA $0.74
- Resistance Level
- CHNR $5.79
- KALA $0.81
- Average True Range (ATR)
- CHNR 0.61
- KALA 0.08
- MACD
- CHNR -0.22
- KALA 0.41
- Stochastic Oscillator
- CHNR 10.34
- KALA 8.84
About CHNR China Natural Resources Inc.
China Natural Resources Inc is engaged in exploration for lead, silver, and other metals in the Inner Mongolia Autonomous Region of the PRC and exploration of attractive opportunities in other sectors. The company has a single operating segment: exploration and mining.
About KALA KALA BIO Inc.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.